Joinn Laboratories(China)Co.,Ltd.
6127.HK
Hong Kong Stock Exchange20.32
HKD
+2.09
- -
Joinn Laboratories(China)Co.,Ltd.
6127.HK
(Hong Kong Stock Exchange)
Recent
price
20.32
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Joinn Laboratories (China) Co., Ltd. (6127.HK) is a China-based contract research organization principally engaged in preclinical pharmacology and toxicology research and evaluation services for new drugs. Founded in 1995 and headquartered in Beijing, the company operates through three main segments: Non-Clinical Studies Services, which encompass drug safety assessment, drug metabolism and pharmacokinetics studies, pharmacology and efficacy studies, and cell-based assay services; Clinical Trial and Related Services, including clinical CRO services, co-managed phase I clinical research units, and bioanalytical services; and Sales of Research Models, involving the design, production, breeding, and sale of research models such as non-human primates and rodents. It also provides specialized evaluations for veterinary drugs, pesticides, medical devices, and services in experimental animals and disease model animals, serving pharmaceutical, biotechnology, and related clients primarily in China, the United States, and internationally through subsidiaries and facilities in locations including Suzhou, Chongqing, Wuzhou, Guangzhou, Shanghai, Richmond (CA), and Worcester (MA). Recent expansions include the operational launch of 8,000 square meter facilities in Suzhou in early 2022, ongoing development of 20,000 square meter animal rooms in Suzhou and 18,000 square meter facilities in Guangzhou as of 2023-2024, and activation of laboratories under subsidiary Joinn Yichuang for drug screening to enhance synergies with discovery services; additionally, the company has advanced investments in integrated bioanalytical solutions, achieving over 50% year-on-year growth in contracts for small nucleic acid and innovative ADC projects in 2024-2025, alongside strategic funding commitments such as RMB130 million paid in 2022 toward a RMB200 million subscription in the Yuanfeng fund and a 2022 partnership with Beiguang Huagai. In 2024, Joinn continued to bolster capabilities in in-vivo and in-vitro drug analysis, organoid production, and one-stop services from target discovery to clinical validation, while its affiliate JOINN Biologics expanded biologics CDMO offerings with Series A and B funding exceeding $260 million to support complex modalities like monoclonal antibodies, bispecifics, and ADCs.